Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-10,300
Closed -$1.38M 42
2022
Q3
$1.38M Sell
10,300
-3,200
-24% -$459K 0.05% 465
2022
Q2
$2.07M Sell
13,500
-1,700
-11% -$260K 0.08% 337
2022
Q1
$2.46M Buy
15,200
+9,000
+145% +$1.31M 0.08% 274
2021
Q4
$839K Sell
6,200
-7,200
-54% -$851K 0.03% 619
2021
Q3
$1.45M Buy
13,400
+7,600
+131% +$868K 0.05% 596
2021
Q2
$653K Sell
5,800
-3,300
-36% -$372K 0.02% 849
2021
Q1
$985K Sell
9,100
-19,700
-68% -$2.11M 0.03% 661
2020
Q4
$3.09M Buy
+28,800
New +$2.77M 0.14% 165

Other funds holding ABBV

Point72 Hong Kong's ABBV Position: Q3 2025 in Review

Point72 Hong Kong sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 120,836 shares — an estimated $22.4M sold.

Point72 Hong Kong first reported a position in ABBV in Q4 2014 and held it in 16 quarters. The position peaked at $22.4M in Q2 2025. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Point72 Hong Kong reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 120,836 AbbVie shares in Q3 2025, an estimated $22.4M.
  • Point72 Hong Kong first reported a position in AbbVie in Q4 2014 and held it in 16 quarters.
  • Point72 Hong Kong's AbbVie position peaked at $22.4M in Q2 2025.
  • 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.